<DOC DOCNO="nw/wsj/23/wsj_2382@2382@wsj@nw@en@on">
<TEXT PARTNO="000">
<COREF ID="0" TYPE="IDENT"><COREF ID="1" TYPE="IDENT">Food and Drug Administration</COREF> spokesman Jeff Nesbit</COREF> said 0 <COREF ID="1" TYPE="IDENT">the agency</COREF> has turned over evidence in <COREF ID="3" TYPE="IDENT"><COREF ID="3" TYPE="IDENT">a criminal investigation</COREF> concerning <COREF ID="5" TYPE="IDENT">Vitarine Pharmaceuticals Inc.</COREF></COREF> to <COREF ID="6" TYPE="IDENT"><COREF ID="6" TYPE="IDENT">the U.S. Attorney 's office</COREF> in Baltimore</COREF> .
Neither <COREF ID="5" TYPE="IDENT">Vitarine</COREF> nor <COREF ID="11" TYPE="IDENT"><COREF ID="11" TYPE="IDENT">any</COREF> of <COREF ID="1" TYPE="IDENT">the Springfield Gardens , N.Y. , company 's</COREF> officials or employees</COREF> have been charged *-1 with any crimes .
<COREF ID="5" TYPE="IDENT">Vitarine</COREF> won approval *PRO* to market <COREF ID="19" TYPE="IDENT"><COREF ID="19" TYPE="IDENT">a version</COREF> of a blood pressure medicine</COREF> but acknowledged that <COREF ID="5" TYPE="IDENT">it</COREF> substituted <COREF ID="52" TYPE="IDENT">a SmithKline Beecham PLC product</COREF> as <COREF ID="32" TYPE="IDENT"><COREF ID="5" TYPE="IDENT">its</COREF> own</COREF> in <COREF ID="26" TYPE="IDENT">tests</COREF> .
<COREF ID="0" TYPE="IDENT">Mr. Nesbit</COREF> also said 0 <COREF ID="1" TYPE="IDENT">the FDA</COREF> has asked <COREF ID="29" TYPE="IDENT">Bolar Pharmaceutical Co.</COREF> *PRO*-1 to <COREF ID="34" TYPE="IDENT">recall</COREF> at the retail level <COREF ID="32" TYPE="IDENT"><COREF ID="29" TYPE="IDENT">its</COREF> urinary tract antibiotic</COREF> .
But so far <COREF ID="29" TYPE="IDENT">the company</COREF> has n't complied with <COREF ID="34" TYPE="IDENT">that request</COREF> , <COREF ID="0" TYPE="IDENT">the spokesman</COREF> said 0 *T*-1 .
<COREF ID="29" TYPE="IDENT"><COREF ID="37" TYPE="APPOS" SUBTYPE="HEAD">Bolar</COREF> , <COREF ID="37" TYPE="APPOS" SUBTYPE="ATTRIB">the subject of <COREF ID="40" TYPE="IDENT"><COREF ID="40" TYPE="IDENT">a criminal investigation</COREF> by <COREF ID="1" TYPE="IDENT">the FDA</COREF> and <COREF ID="44" TYPE="IDENT"><COREF ID="44" TYPE="IDENT">the Inspector General 's office</COREF> of the Health and Human Services Department</COREF></COREF></COREF> ,</COREF> only agreed *PRO*-1 to recall <COREF ID="48" TYPE="IDENT"><COREF ID="48" TYPE="IDENT">two strengths</COREF> of <COREF ID="32" TYPE="IDENT"><COREF ID="32" TYPE="IDENT"><COREF ID="29" TYPE="IDENT">its</COREF> version</COREF> of <COREF ID="52" TYPE="IDENT">Macrodantin</COREF></COREF></COREF> `` as far down as <COREF ID="53" TYPE="IDENT"><COREF ID="53" TYPE="IDENT">direct customers</COREF> , mostly wholesalers</COREF> , '' <COREF ID="0" TYPE="IDENT">Mr. Nesbit</COREF> said 0 *T*-2 .
<COREF ID="29" TYPE="IDENT"><COREF ID="29" TYPE="IDENT">Bolar</COREF> , of <COREF ID="59" TYPE="IDENT"><COREF ID="59" TYPE="IDENT">Copiague</COREF> , N.Y. ,</COREF></COREF> earlier began <COREF ID="62" TYPE="IDENT"><COREF ID="62" TYPE="IDENT">a voluntary recall</COREF> of <COREF ID="48" TYPE="IDENT"><COREF ID="48" TYPE="IDENT">both <COREF ID="29" TYPE="IDENT">its</COREF> 100 milligram and 50 milligram versions</COREF> of <COREF ID="52" TYPE="IDENT">the drug</COREF></COREF></COREF> .
<COREF ID="1" TYPE="IDENT">The FDA</COREF> has said 0 <COREF ID="1" TYPE="IDENT">it</COREF> presented <COREF ID="69" TYPE="IDENT"><COREF ID="69" TYPE="IDENT">evidence</COREF> 0 <COREF ID="1" TYPE="IDENT">it</COREF> uncovered *T*-1 *ICH*-2</COREF> to <COREF ID="29" TYPE="IDENT">the company</COREF> indicating that <COREF ID="29" TYPE="IDENT">Bolar</COREF> substituted <COREF ID="52" TYPE="IDENT">the brand - name product</COREF> for <COREF ID="32" TYPE="IDENT"><COREF ID="29" TYPE="IDENT">its</COREF> own</COREF> *PRO*-3 to gain government approval *PRO* to sell <COREF ID="80" TYPE="IDENT"><COREF ID="80" TYPE="IDENT">generic versions</COREF> of <COREF ID="52" TYPE="IDENT">Macrodantin</COREF></COREF> .
<COREF ID="29" TYPE="IDENT">Bolar</COREF> has denied that <COREF ID="29" TYPE="IDENT">it</COREF> switched <COREF ID="52" TYPE="IDENT">the brand - name product</COREF> for <COREF ID="32" TYPE="IDENT"><COREF ID="29" TYPE="IDENT">its</COREF> own</COREF> in <COREF ID="26" TYPE="IDENT">such testing</COREF> .
</TEXT>
</DOC>
